secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001104659-25-112682
Event type: debt
Sentiment:  negative
Materiality: 0.60
Item codes: 1.01, 2.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Brainstorm Cell Therapeutics issues $143,750 note to Labrys Fund II, reports Q3 2025 results
--------------------------------------------------------------------------------

- Entered securities purchase agreement with Labrys Fund II for a promissory note of $143,750, including $18,750 original issue discount, receiving net proceeds of $121,500.
- Note requires six payments of $22,589 starting May 2026, matures November 10, 2026, and is convertible at 25% discount to lowest trading price over 20 days, subject to 4.99% ownership cap.
- Q3 2025 net loss was $2.1 million ($0.19 per share); cash and equivalents were $0.23 million as of September 30, 2025.
- R&D expenses were $0.9 million and G&A expenses were $1.1 million, both down from prior year quarter.
- FDA cleared Phase 3b ENDURANCE trial of NurOwn for ALS; a Citizen Petition was filed by ALS community representatives seeking renewed regulatory review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925112682/0001104659-25-112682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925112682/tm2531319d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-112682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer